Yan He
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yan He has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Xiaochun Xie
National Engineering Research Center for Tissue Restoration and Reconstruction South China University of Technology Guangzhou Guangdong 510006 China
2 shared publications- Chao Yang
Department of Orthopaedics, Center for Orthopaedic Surgery, The Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, 510630, China
1 shared publication Dan Shao
National Engineering Research Center for Tissue Restoration and Reconstruction South China University of Technology Guangzhou Guangdong 510006 China
1 shared publication- Difei Wang
Department of Gerontology and Geriatrics Shengjing Hospital of China Medical University Shenyang China
1 shared publication Fangman Chen
National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangdong, 510006, China
1 shared publicationJiali Liu
Department of Orthopedics, Academy of Orthopedics-Guangdong Province, Orthopedic Hospital of Guangdong Province, Guangdong Provincial Key Laboratory of Bone and Joint Degenerative Diseases, The Third Affiliated Hospital of Southern Medical University, Guangzhou, 510630, China; School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou, Guangdong, 511442, China
1 shared publication
Latest Publications
- Open Access
- 2 October 2025
- Published by Wiley in Advanced Science
- Vol. 12 (47) , e11813
Enhanced Selenium Supplement Extends Lifespan and Delays Multi‐Organs Aging by Regulating the Sik1 Pathway Through Maintaining Calcium Homeostasis
Selenium supplementation has potential in treating aging‐related disorders like neurodegenerative and cardiovascular diseases, but its use is limited by poor bioavailability, a narrow therapeutic window, and unclear mechanisms. To overcome this, redox‐dual‐responsive diselenide‐bridged mesoporous silica nanoparticles (SeMSNs) are developed. SeMSNs effectively reduce oxidative stress and downregulate senescence markers (p16, p21), suppressing senescence in both naturally aged primary mouse embryonic fibroblasts (MEFs) and H 2 O 2 ‐induced HEK‐293T cells. They show prolonged antioxidant effects ( p < 0.05) and lower cytotoxicity ( p < 0.01) than commercial selenomethionine. In aged mice, SeMSNs extend lifespan, reduce frailty, and improve age‐related conditions, including muscle atrophy, renal dysfunction, cognitive decline, and hepatic steatosis, while restoring metabolic balance. They outperform conventional organically‐bridged mesoporous silica nanoparticles (MSNs) and disulfide‐bridged MSNs (SMSNs) ( p < 0.01). Mechanistically, SeMSNs upregulate selenoproteins (GPx1, SelK), suppress endoplasmic reticulum (ER) stress‐mediated calcium release, maintain calcium homeostasis, and inhibit NFATc2‐driven Sik1 transcription, reducing p21/p16. Clinical data confirm an inverse correlation between selenium levels and aging biomarkers ( p < 0.0001). SeMSNs also restore adipogenic differentiation in human adipose progenitor cells via calcium‐NFATc2‐Sik1 signaling. These results demonstrate the superiority of SeMSNs over traditional selenium forms, providing a nanotherapeutic strategy to combat multi‐organ aging and promote healthy longevity.
- 2 October 2025
- Published by Wiley in Advanced Science
- Vol. 12 (47) , e11813
Open AccessEnhanced Selenium Supplement Extends Lifespan and Delays Multi‐Organs Aging by Regulating the Sik1 Pathway Through Maintaining Calcium Homeostasis
Selenium supplementation has potential in treating aging‐related disorders like neurodegenerative and cardiovascular diseases, but its use is limited by poor bioavailability, a narrow therapeutic window, and unclear mechanisms. To overcome this, redox‐dual‐responsive diselenide‐bridged mesoporous silica nanoparticles (SeMSNs) are developed. SeMSNs effectively reduce oxidative stress and downregulate senescence markers (p16, p21), suppressing senescence in both naturally aged primary mouse embryonic fibroblasts (MEFs) and H 2 O 2 ‐induced HEK‐293T cells. They show prolonged antioxidant effects ( p < 0.05) and lower cytotoxicity ( p < 0.01) than commercial selenomethionine. In aged mice, SeMSNs extend lifespan, reduce frailty, and improve age‐related conditions, including muscle atrophy, renal dysfunction, cognitive decline, and hepatic steatosis, while restoring metabolic balance. They outperform conventional organically‐bridged mesoporous silica nanoparticles (MSNs) and disulfide‐bridged MSNs (SMSNs) ( p < 0.01). Mechanistically, SeMSNs upregulate selenoproteins (GPx1, SelK), suppress endoplasmic reticulum (ER) stress‐mediated calcium release, maintain calcium homeostasis, and inhibit NFATc2‐driven Sik1 transcription, reducing p21/p16. Clinical data confirm an inverse correlation between selenium levels and aging biomarkers ( p < 0.0001). SeMSNs also restore adipogenic differentiation in human adipose progenitor cells via calcium‐NFATc2‐Sik1 signaling. These results demonstrate the superiority of SeMSNs over traditional selenium forms, providing a nanotherapeutic strategy to combat multi‐organ aging and promote healthy longevity.
- 25 October 2024
- Published by Elsevier in Biomaterials
- Vol. 315, 122919
Bioactive mesoporous silica materials-assisted cancer immunotherapy
- 25 October 2024
- Published by Elsevier in Biomaterials
- Vol. 315, 122919
Bioactive mesoporous silica materials-assisted cancer immunotherapy